Kunte, Siddharth http://orcid.org/0000-0002-5544-3410
Rybicki, Lisa
Viswabandya, Auro
Tamari, Roni
Bashey, Asad
Keyzner, Alla
Iqbal, Madiha
Grunwald, Michael R.
Dholaria, Bhagirathbhai http://orcid.org/0000-0003-2371-3655
Elmariah, Hany http://orcid.org/0000-0001-7920-4636
Ozga, Michael
Singh, Anurag
Abedin, Sameem
DeZern, Amy E.
Jones, Richard J.
Gupta, Vikas
Gerds, Aaron T. http://orcid.org/0000-0002-3422-1309
Jain, Tania http://orcid.org/0000-0001-6854-773X
Article History
Received: 21 July 2021
Revised: 29 September 2021
Accepted: 4 October 2021
First Online: 18 October 2021
Competing interests
: M.R.G. has received consulting fees from Abbvie, Agios, Amgen, Astellas, Blueprint Medicines, Bristol Myers Squibb, Cardinal Health, Daiichi Sankyo, Gilead, Incyte, Karius, Pfizer, Premier, Sierra Oncology, Stemline, and Trovagene; research support from Incyte, Genentech/Roche, and Janssen; and owns stock in Medtronic. B.D. reports institutional research support from Takeda, Janssen, Angiocrine, Pfizer, and Poseida, and serves on the advisory board of Jazz. S.A. reports research funding through Helsinn Healthcare, Actinium Pharmaceuticals, and Pfizer and has received consulting fees from Abbvie and Agios. A.D. reports honoraria through Abbvie, Taiho, and Novartis. V.G. reports institutional research funding through Novartis and honoraria through Novartis, BMS-Celgene, Abbvie, Constellation Pharmaceuticals, and Sierra Oncology. A.T.G. reports research funding through Sierra Oncology, Pfizer, Celgene, CTI Biopharma, Incyte Corporation, Roche/Genentech, Imago Biosciences, and Gilead Sciences, and has received consulting fees from Celgene, CTI Biopharma, AstraZeneca/MedImmune, Incyte Corporation, and Apexx Oncology. T.J. reports institutional research support from CTI Biopharma, Incyte and Syneos Health, Consultancy with Targeted Healthcare Communications, advisory board with Care Dx, and Bristol Myers Squibb. The remaining authors do not have any conflicts of interest.